1463484-39-0

Basic information

• Product Name: benzyl3a,4-dihydro-3H-pyrrolo[3,4-c]isoxazole-5(6H)-carboxylate
• Synonyms: benzyl3a,4-dihydro-3H-pyrrolo[3,4-c]isoxazole-5(6H)-carboxylate;EOS-60741;Benzyl 3A,4-Dihydro-3H-Pyrrolo[3,4-C]Isoxazole-5(6H)-Carboxylate(WXC01792)
• CAS NO: 1463484-39-0
• Molecular Formula: C₁₃H₁₄N₂O₃
• Molecular Weight: 245.25392
• Mol File: 1463484-39-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: benzyl3a,4-dihydro-3H-pyrrolo[3,4-c]isoxazole-5(6H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl3a,4-dihydro-3H-pyrrolo[3,4-c]isoxazole-5(6H)-carboxylate(1463484-39-0)
• EPA Substance Registry System: benzyl3a,4-dihydro-3H-pyrrolo[3,4-c]isoxazole-5(6H)-carboxylate(1463484-39-0)

Safety Data

• Hazardous Substances Data: 1463484-39-0(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 370880-76-5 benzyl N-[2-(hydroxyimino)ethyl]-N-(prop-2-en-1-yl)carbamate 
• 569682-60-6 benzyl N-(2,2-dimethoxyethyl)-N-(prop-2-en-1-yl)carbamate 
• 114790-39-5 benzyl N-(2,2-dimethoxyethyl)carbamate 
• 370880-75-4 benzyl N-(2-oxoethyl)-N-(prop-2-en-1-yl)carbamate 

Downstream Products

• 1463484-71-0 benzyl 3-amino-4-(hydroxymethyl)-3-phenyl-pyrrolidine-1-carboxylate 
• 1463484-74-3 benzyl 3-amino-4-(hydroxymethyl)-3-(2-thienyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor

The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer's disease drug target owing to its critical role in the production of amyloid-beta. We have previously reported the clinical development of LY2811376 and LY2886721. L

A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR

The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).

TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE

The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5- fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro- phenyl]-5-methoxy-pyrazine-2-carboxamide.

TETRAHYDROPYRROLOTHIAZINE COMPOUNDS

The present invention provides a compound of Formula (I): wherein R is H or F; and A is:(A), (B), (C) or (D); or a pharmaceutically acceptable salt thereof.

TETRAHYDROPYRROLOTHIAZINE COMPOUNDS

The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.